NFA
PDLI

Nuveen Fund Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Nuveen Fund Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-45,742
Closed -$144K – 490
2016
Q2 		$144K Buy
+45,742
New +$153K 0.02% 427

Other funds holding PDLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Fund Advisors's PDLI Position: Q3 2016 in Review

Nuveen Fund Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q3 2016, closing a stake of 45,742 shares — an estimated $144K sold.

Nuveen Fund Advisors first reported a position in PDLI in Q2 2016 and held it in 1 quarter. The position peaked at $144K in Q2 2016. 197 funds tracked by Wall St. Rank hold PDLI as of Q3 2016.

  • Nuveen Fund Advisors reported no remaining PDL BioPharma, Inc. position as of Q3 2016 after selling out during the quarter.
  • Nuveen Fund Advisors sold 45,742 PDL BioPharma, Inc. shares in Q3 2016, an estimated $144K.
  • Nuveen Fund Advisors first reported a position in PDL BioPharma, Inc. in Q2 2016 and held it in 1 quarter.
  • Nuveen Fund Advisors's PDL BioPharma, Inc. position peaked at $144K in Q2 2016.
  • 197 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2016.

Based on Nuveen Fund Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.